Neurofit Participates in KCR 2023... Showcases Alzheimer's Disease Imaging Biomarker Analysis Technology

Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 22nd that it participated in the 79th Korean Congress of Radiology (KCR 2023).

At this conference, Neurofit focused on introducing its main brain imaging analysis products: the brain neurodegeneration imaging analysis software ‘Neurophet AQUA’ and the PET automatic imaging analysis software ‘Neurophet SCALE PET’.

Neurophet AQUA is brain imaging analysis software that analyzes brain MRI (magnetic resonance imaging) using AI technology to assess brain atrophy and white matter degeneration observed in degenerative brain diseases such as Alzheimer’s disease and vascular dementia. It can segment and analyze MRI scans within 5 minutes regardless of race, age, or gender.

Neurophet SCALE PET is software that combines PET (positron emission tomography) images with MRI to quantitatively analyze Alzheimer’s disease biomarkers. When diagnosing Alzheimer’s disease, the most common type of dementia, it confirms the deposition of amyloid beta protein, an Alzheimer’s biomarker, in the brain cortex from PET images. Neurophet SCALE PET automatically provides quantitative values of amyloid beta protein deposition in detailed brain regions, enabling fast and accurate analysis.

Neurofit also showcased technology related to Alzheimer’s disease treatments soon to be launched by global pharmaceutical companies. Recently developed Alzheimer’s treatments such as lecanemab and donanemab are anti-amyloid antibody therapies that remove amyloid beta protein accumulated in the brain. It is essential to verify the presence of amyloid beta protein deposition in the brain cortex before and after treatment administration, and Neurophet SCALE PET allows quantitative confirmation of amyloid beta protein deposition.

Patients receiving Alzheimer’s treatments often experience ‘ARIA (Amyloid-Related Imaging Abnormalities)’ side effects, and Neurofit possesses vascular neuropathology quantification technology capable of monitoring and analyzing ARIA side effects.

Additionally, at the KCR 2023 ‘Scientific Session,’ Neurofit presented a research abstract related to brain imaging analysis. The presentation topic was ‘A comprehensive multi-dimensional T2-FLAIR segmentation method for demyelination and white matter lesion analysis.’

Bin Jungil, CEO of Neurofit, stated, “In July, the American Alzheimer’s Association and the National Institute on Aging added vascular brain injury biomarkers to the Alzheimer’s disease diagnostic guidelines. Since 2020, through the government-led Dementia Overcoming R&D Project Group, Neurofit has been conducting research and development not only on existing Alzheimer’s imaging biomarkers but also on vascular brain injury biomarkers based on brain imaging for dementia diagnosis and prognosis prediction.”

He continued, “We will devote ourselves to research and development to become a leading company in Alzheimer’s diagnosis and prognosis prediction by providing quantitative values of brain neurodegeneration, vascular neuropathology, amyloid beta protein, and tau protein through brain imaging analysis based on our proprietary technology.”

Meanwhile, KCR 2023, which began on the 20th, is being held at COEX in Seoul until the 23rd.

This content was produced with the assistance of AI translation services.